Tenascin-C levels in synovial fluid are elevated after injury to the human and canine joint and correlate with markers of inflammation and matrix degradation

Osteoarthritis and Cartilage

Volumn 21, Issue 2, 2013, Pages 339-345

  Chockalingam, P S ^a   Glasson, S S ^a   Lohmander, L S ^b,c  

^a PFIZER INC   (United States)

^b LUND UNIVERSITY   (Sweden)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Biomarker; Cartilage; Joint injury; Synovial fluid; Tenascin C

Indexed keywords

AGGRECANASE; INTERSTITIAL COLLAGENASE; STROMELYSIN; TENASCIN;

ACUTE INFLAMMATORY ARTHRITIS; ADOLESCENT; ADULT; ANTERIOR CRUCIATE LIGAMENT RUPTURE; ARTHRITIS; ARTICLE; CONTROLLED STUDY; CORRELATIONAL STUDY; CROSS-SECTIONAL STUDY; DISEASE SEVERITY; EXPERIMENTAL DOG; FEMALE; HUMAN; HUMAN TISSUE; JOINT INJURY; KNEE INSTABILITY; KNEE MENISCUS RUPTURE; KNEE OSTEOARTHRITIS; MAJOR CLINICAL STUDY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN SECRETION; SYNOVIAL FLUID;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AGGRECANS; ANIMALS; ARTHRITIS; BIOLOGICAL MARKERS; CARTILAGE, ARTICULAR; COHORT STUDIES; CROSS-SECTIONAL STUDIES; DISEASE MODELS, ANIMAL; DOGS; FEMALE; HUMANS; JOINT DISEASES; KNEE INJURIES; MALE; MATRIX METALLOPROTEINASE 1; MATRIX METALLOPROTEINASE 3; MIDDLE AGED; OSTEOARTHRITIS, KNEE; SYNOVIAL FLUID; TENASCIN; YOUNG ADULT;

EID: 84872668477     PISSN: 10634584     EISSN: 15229653     Source Type: Journal    
DOI: 10.1016/j.joca.2012.10.016     Document Type: Article

References (46)

1. Chiquet-Ehrismann R. Tenascins, a growing family of extracellular matrix proteins. Experientia 1995, 51:853-862.
2. Chiquet-Ehrismann R., Hagios C., Matsumoto K. The tenascin gene family. Perspect Dev Neurobiol 1994, 2:3-7.
3. Hagios C., Brown-Luedi M., Chiquet-Ehrismann R. Tenascin-Y, a component of distinctive connective tissues, supports muscle cell growth. Exp Cell Res 1999, 253:607-617.
4. Jones F.S., Hoffman S., Cunningham B.A., Edelman G.M. A detailed structural model of cytotactin: protein homologies, alternative RNA splicing, and binding regions. Proc Natl Acad Sci U S A 1989, 86:1905-1909.
5. Midwood K.S., Orend G. The role of tenascin-C in tissue injury and tumorigenesis. J Cell Commun Signal 2009, 3:287-310.
6. Oberhauser A.F., Marszalek P.E., Erickson H.P., Fernandez J.M. The molecular elasticity of the extracellular matrix protein tenascin. Nature 1998, 393:181-185.
7. Chiquet-Ehrismann R., Mackie E.J., Pearson C.A., Sakakura T. Tenascin: an extracellular matrix protein involved in tissue interactions during fetal development and oncogenesis. Cell 1986, 47:131-139.
8. Yoshida T., Yoshimura E., Numata H., Sakakura Y., Sakakura T. Involvement of tenascin-C in proliferation and migration of laryngeal carcinoma cells. Virchows Arch 1999, 435:496-500.
9. Mackie E.J., Murphy L.I. The role of tenascin-C and related glycoproteins in early chondrogenesis. Microsc Res Tech 1998, 43:102-110.
10. Pacifici M., Iwamoto M., Golden E.B., Leatherman J.L., Lee Y.S., Chuong C.M. Tenascin is associated with articular cartilage development. Dev Dyn 1993, 198:123-134.
11. Chevalier X., Groult N., Larget-Piet B., Zardi L., Hornebeck W. Tenascin distribution in articular cartilage from normal subjects and from patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum 1994, 37:1013-1022.
12. Veje K., Hyllested-Winge J.L., Ostergaard K. Topographic and zonal distribution of tenascin in human articular cartilage from femoral heads: normal versus mild and severe osteoarthritis. Osteoarthritis Cartilage 2003, 11:217-227.
13. Salter D.M. Tenascin is increased in cartilage and synovium from arthritic knees. Br J Rheumatol 1993, 32:780-786.
14. Pfander D., Rahmanzadeh R., Scheller E.E. Presence and distribution of collagen II, collagen I, fibronectin, and tenascin in rabbit normal and osteoarthritic cartilage. J Rheumatol 1999, 26:386-394.
15. Goh F.G., Piccinini A.M., Krausgruber T., Udalova I.A., Midwood K.S. Transcriptional regulation of the endogenous danger signal tenascin-C: a novel autocrine loop in inflammation. J Immunol 2010, 184:2655-2662.
16. Schmidt-Rohlfing B., Gavenis K., Kippels M., Schneider U. New potential markers for cartilage degradation of the knee joint. Scand J Rheumatol 2002, 31:151-157.
17. Hasegawa M., Hirata H., Sudo A., Kato K., Kawase D., Kinoshita N., et al. Tenascin-C concentration in synovial fluid correlates with radiographic progression of knee osteoarthritis. J Rheumatol 2004, 31:2021-2026.
18. Midwood K., Sacre S., Piccinini A.M., Inglis J., Trebaul A., Chan E., et al. Tenascin-C is an endogenous activator of toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med 2009, 15:774-780.
19. Patel L., Sun W., Glasson S., Morris E., Flannery C., Chockalingam P. Tenascin-C induces inflammatory mediators and matrix degradation in osteoarthritic cartilage. BMC Musculoskelet Disord 2011, 12:164.
20. Dahlberg L., Ryd L., Heinegard D., Lohmander L.S. Proteoglycan fragments in joint fluid. Influence of arthrosis and inflammation. Acta Orthop Scand 1992, 63:417-423.
21. Brandt K.D., Braunstein E.M., Visco D.M., O'Connor B., Heck D., Albrecht M. Anterior (cranial) cruciate ligament transection in the dog: a bona fide model of osteoarthritis, not merely of cartilage injury and repair. J Rheumatol 1991, 18:436-446.
22. Brandt K.D., Myers S.L., Burr D., Albrecht M. Osteoarthritic changes in canine articular cartilage, subchondral bone, and synovium fifty-four months after transection of the anterior cruciate ligament. Arthritis Rheum 1991, 34:1560-1570.
23. Imanaka-Yoshida K., Hiroe M., Yasutomi Y., Toyozaki T., Tsuchiya T., Noda N., et al. Tenascin-C is a useful marker for disease activity in myocarditis. J Pathol 2002, 197:388-394.
24. Larsson S., Lohmander L.S., Struglics A. Synovial fluid level of aggrecan ARGS fragments is a more sensitive marker of joint disease than glycosaminoglycan or aggrecan levels: a cross-sectional study. Arthritis Res Ther 2009, 11:R92.
25. Chockalingam P.S., Sun W., Rivera-Bermudez M.A., Zeng W., Dufield D.R., Larsson S., et al. Elevated aggrecanase activity in a rat model of joint injury is attenuated by an aggrecanase specific inhibitor. Osteoarthritis Cartilage 2011, 19:315-323.
26. Lohmander L.S., Ionescu M., Jugessur H., Poole A.R. Changes in joint cartilage aggrecan after knee injury and in osteoarthritis. Arthritis Rheum 1999, 42:534-544.
27. Lohmander L.S., Saxne T., Heinegard D.K. Release of cartilage oligomeric matrix protein (COMP) into joint fluid after knee injury and in osteoarthritis. Ann Rheum Dis 1994, 53:8-13.
28. Kobayashi T., Yoshihara Y., Samura A., Yamada H., Shinmei M., Roos H., et al. Synovial fluid concentrations of the C-propeptide of type II collagen correlate with body mass index in primary knee osteoarthritis. Ann Rheum Dis 1997, 56:500-503.
29. Lohmander L.S., Atley L.M., Pietka T.A., Eyre D.R. The release of crosslinked peptides from type II collagen into human synovial fluid is increased soon after joint injury and in osteoarthritis. Arthritis Rheum 2003, 48:3130-3139.
30. Lohmander L.S., Hoerrner L.A., Lark M.W. Metalloproteinases, tissue inhibitor, and proteoglycan fragments in knee synovial fluid in human osteoarthritis. Arthritis Rheum 1993, 36:181-189.
31. Lohmander L.S., Roos H., Dahlberg L., Hoerrner L.A., Lark M.W. Temporal patterns of stromelysin-1, tissue inhibitor, and proteoglycan fragments in human knee joint fluid after injury to the cruciate ligament or meniscus. J Orthop Res 1994, 12:21-28.
32. Tchetverikov I., Lohmander L.S., Verzijl N., Huizinga T.W., TeKoppele J.M., Hanemaaijer R., et al. MMP protein and activity levels in synovial fluid from patients with joint injury, inflammatory arthritis, and osteoarthritis. Ann Rheum Dis 2005, 64:694-698.
33. Hasegawa M., Nakoshi Y., Muraki M., Sudo A., Kinoshita N., Yoshida T., et al. Expression of large tenascin-C splice variants in synovial fluid of patients with rheumatoid arthritis. J Orthop Res 2007, 25:563-568.
34. Lorenz H., Wenz W., Ivancic M., Steck E., Richter W. Early and stable upregulation of collagen type II, collagen type I and YKL40 expression levels in cartilage during early experimental osteoarthritis occurs independent of joint location and histological grading. Arthritis Res Ther 2005, 7:R156-R165.
35. Nakoshi Y., Hasegawa M., Akeda K., Iino T., Sudo A., Yoshida T., et al. Distribution and role of tenascin-C in human osteoarthritic cartilage. J Orthop Sci 2010, 15:666-673.
36. Sofat N., Robertson S.D., Hermansson M., Jones J., Mitchell P., Wait R. Tenascin-C fragments are endogenous inducers of cartilage matrix degradation. Rheumatol Int 2012, 32:2809-2817.
37. Cheng T., Maddox N.C., Wong A.W., Rahnama R., Kuo A.C. Comparison of gene expression patterns in articular cartilage and dedifferentiated articular chondrocytes. J Orthop Res 2012, 30:234-245.
38. Siri A., Knäuper V., Veirana N., Caocci F., Murphy G., Zardi L. Different susceptibility of small and large human tenascin-c isoforms to degradation by matrix metalloproteinases. J Biol Chem 1995, 270:8650-8654.
39. Bobacz K., Sunk I.G., Hofstaetter J.G., Amoyo L., Toma C.D., Akira S., et al. Toll-like receptors and chondrocytes: the lipopolysaccharide-induced decrease in cartilage matrix synthesis is dependent on the presence of toll-like receptor 4 and antagonized by bone morphogenetic protein 7. Arthritis Rheum 2007, 56:1880-1893.
40. Ruhmann M., Piccinini A.M., Kong P.L., Midwood K.S. Endogenous activation of adaptive immunity. Tenascin-C drives interleukin-17 synthesis in murine arthritic joint disease. Arthritis Rheum 2012, 64:2179-2190.
41. Liu-Bryan R., Terkeltaub R. The growing array of innate inflammatory ignition switches in osteoarthritis. Arthritis Rheum 2012, 64:2055-2058.
42. Zhen E.Y., Brittain I.J., Laska D.A., Mitchell P.G., Sumer E.U., Karsdal M.A., et al. Characterization of metalloproteinase products of human articular cartilage. Arthritis Rheum 2008, 58:2420-2431.
43. Simkin P.A. Assessing biomarkers in synovial fluid: consider the kinetics of clearance. Osteoarthritis Cartilage 2012, S1063-4584(12)00990-9 (Epub ahead of print).
44. Savarese J.J., Erickson H., Scully S.P. Articular chondrocyte tenascin-C production and assembly into de novo extracellular matrix. J Orthop Res 1996, 14:273-281.
45. Day J.M., Olin A.I., Murdoch A.D., Canfield A., Sasaki T., Timpl R., et al. Alternative splicing in the aggrecan G3 domain influences binding interactions with tenascin-C and other extracellular matrix proteins. J Biol Chem 2004, 279:12511-12518.
46. Okamura N., Hasegawa M., Nakoshi Y., Iino T., Sudo A., Imanaka-Yoshida K., et al. Deficiency of tenascin-C delays articular cartilage repair in mice. Osteoarthritis Cartilage 2010, 18:839-848.